|
1795
Adoptive Immunotherapy in Ovarian Cancer with
Monocyte Derived Activated Killer Cells Mixed with Anti HER2/neu +
Anti Fc Gamma RI Bispecific Antibody. A de Gramont, D Gangji,
C Louvet, Ml Garcia, D Tardy, Jl Romet-Lemonne, Hosp St Antoine,
Paris, France; Erasme Hosp, Brussels, Belgium; IDM, Paris,
France.
Aim: To assess the safety and the efficacy of intraperitoneal
(i.p.) injections of monocyte derived activated killer cells (MAK)
mixed with anti HER2/neu + anti Fc gamma RI bispecific monoclonal
antibody on the residual disease (RD) of ovarian cancer after
surgery and chemotherapy. Patients and method: Following 2nd look
examination after surgery and chemotherapy, patients with
microscopic (positive biopsy) or macroscopic (< 1 cm) RD were
included. They received 6 i.p. of autologous MAK cells mixed with a
humanised bispecific antibody anti HER2/neu + anti Fc gamma RI (MDX
210 - Medarex). Mononuclear cells obtained by apheresis were
cultured during 6 days with GM-CSF using the MAK cell Processor
(IDM). They were then activated by g-interferon for 16 hours and
elutriated. At the end of the procedure, about 1 milliard MAK cells
with > 90% purity and viability were collected and injected i.p.
using a subcutaneous chamber and an intraperitoneal catheter.
Efficacy was evaluated at the time of a 3rd look performed 3 months
after initiation of cell therapy. Results: 14 eligible patients were
included between December 1997 and June 1999. 8 patients
demonstrated HER2/neu overexpression at the surface of ovarian tumor
cells. At the time of the 3rd look, progressive disease was observed
in 5 patients, no change in 3 and a complete clinical response was
seen in 6 patients (including multiple negative biopsies in 5). No
serious adverse events related to therapy nor grade 3 / 4 (NCI-CTC)
side effect occurred during the apheresis and the treatment.
Conclusion: Treatment with monocyte derived activated killer cells
mixed with anti HER2/neu + anti Fc gamma RI monoclonal bispecific
antibody appeared to be feasible and safe. Further controlled
studies are required to confirm efficacy.
|
